Ibrance, Prevnar 13 Q2 Sales Validate Pfizer's R&D Investments
This article was originally published in The Pink Sheet Daily
Executive Summary
Novel products help the company beat consensus estimates for the quarter, and the pharma giant pointed to immuno-oncology and PCSK9 as investments that will provide greater returns in the future. Additional acquisitions and a potential split remain on the table, execs say.